Wells Fargo & Company Design Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $507 Billion
- Q3 2025
A detailed history of Wells Fargo & Company transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 18,317 shares of DSGN stock, worth $134,996. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,317
Previous 20,284
9.7%
Holding current value
$134,996
Previous $68,000
101.47%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding DSGN
# of Institutions
98Shares Held
34.1MCall Options Held
0Put Options Held
0-
Sr One Capital Management, LP6.53MShares$48.1 Million11.31% of portfolio
-
Logos Global Management LP San Francisco, CA3.66MShares$26.9 Million3.19% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.34MShares$24.6 Million0.05% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$17 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$14.4 Million0.62% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $411M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...